Pfizer R&D czars big on collaboration, quiet on cuts

One of the hottest topics in drug discovery circles right now is how the big Pfizer/Wyeth merger will play out in the companies' labs. Analysts have already been buzzing about the likelihood of billions of dollars in cuts as the two R&D operations are melded into one big outfit. But Martin Mackay and Mikael Dolsten, who will head up the company's two wings of research, are publicly concentrating more on the structure of their new drug discovery domain rather than the number of scientists likely to get laid off. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.